VoxCell BioInnovation Inc. (“VoxCell”), a developer of bioprinted vascularized human tissue models for preclinical drug development, and adMare BioInnovations (“adMare”), Canada’s life sciences company creation engine, today announced a research partnership to validate the scientific and commercial potential of a novel antibody-based immune-modulating therapy using VoxCell’s human-relevant vascularized cancer tissue models.
VoxCell’s platform brings together human tumor, immune, and stromal compartments alongside a perfused, endothelial-lined vasculature in a single bioprinted construct. The result is a human-like system that recapitulates antibody delivery, immune activity, and downstream tumor biology, with quantitative readouts across efficacy and safety endpoints that legacy in vitro and in vivo models struggle to deliver.
The partnership comes as the U.S. Food and Drug Administration advances its plan to significantly reduce animal testing for monoclonal antibodies and other biologics, expanding the use of New Approach Methodologies (NAMs), including human-relevant 3D tissue platforms, organ-on-chip systems, and AI-based models, to improve preclinical translation rates.
“adMare’s mission is to translate breakthrough scientific discoveries into strong, investable Canadian life science companies and new therapies that reach patients,” said Matthew J. Carlyle, President and CEO of adMare BioInnovations. “That requires more than capital – it requires hands-on company building support and access to the right commercial R&D tools early on. By integrating VoxCell’s human-relevant vascularized tissue platform into our scientific and commercial validation process we can generate stronger preclinical safety and efficacy evidence sooner. This helps us de-risk innovation, create long-term value, and turn promising science into scalable, globally competitive Canadian companies.”
VoxCell’s platform is built on a high-resolution bioprinting process that produces perfusable vascular networks inside human-like tissue, addressing a long-standing gap in 3D cell culture. The models are designed to support large biologics, immune-modulating therapies, and other modalities where antibody transport, endothelial barrier function, and immune complexity drive in vivo behavior.
“Animal models often miss the biology that determines whether a human drug works,” said Dr. Karolina Valente, Chief Executive Officer and Chief Scientific Officer of VoxCell. “Our vascularized tissues bring perfusion, endothelial barriers, immune cells, and stroma into one human-relevant system. Working with adMare on a novel biologic is exactly the use case the FDA had in mind when it called for more predictive, human-relevant tools. The result is better decisions earlier, and fewer animals used along the way.”
Data generated under the collaboration will inform adMare’s program development and contribute to a broader effort to qualify VoxCell’s vascularized cancer tissue model as a reference NAM for immuno-oncology biologics.
